NIKKEI 225
32,371.90 +56.85 (+0.18%) HANG SENG
17,611.87 +144.97 (+0.83%) CRUDE OIL
93.84 +0.16 (+0.17%) GOLD FUTURES
1,893.60 +2.70 (+0.14%) DOW
33,550.27 -68.61 (-0.20%) Bitcoin GBP
21,693.15 +138.44 (+0.64%)
Pfizer Inc. (0Q1N.L)
| Previous close | 50.58 |
| Open | 50.82 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 50.26 - 50.82 |
| 52-week range | 33.27 - 54.90 |
| Volume | |
| Avg. volume | 236,987 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 31 Oct 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.30 |
- Yahoo Finance Video
New COVID vaccine rollout running into insurance, supply roadblocks
The rollout of new COVID-19 vaccines is being obstructed by insurance and supply roadblocks, as customers experience issues with getting insurers to agree on vaccine coverage. The Department of Health and Human Services wrote a letter to insurers stating, "Your obligation as a plan or issuer to ensure that your members have coverage for COVID-19 vaccines without cost sharing is not conditional upon parties' compliance." Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Business WirePfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
NEW YORK, September 22, 2023--Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) following a favorable vote for ABRYSVO™ [Respiratory Syncytial Virus Vaccine], the company’s bivalent RSV prefusion F (RSVpreF) vaccine, as a maternal immunization. This is the first-ever fall in which eligible individuals can receive Pfizer vaccines
- Yahoo Finance Video
Moderna, Pfizer on the move on concerns about weak demand for COVID vaccines
Shares of Moderna (MRNA) and Pfizer (PFE) are on the move after Pfizer CFO David Denton projected a COVID vaccination rate of only 24% this year in the U.S. The demand for COVID vaccinations has dwindled, with data indicating it's less than half of what is expected for flu shots. Despite Moderna's efforts to expand its business, it remains heavily reliant on COVID vaccinations and booster shots. Yahoo Finance's Seana Smith and Brad Smith discuss the details of how the declining demand for COVID immunizations could affect vaccine makers moving forward.
